Table 1.
Summary data from patient cohorts used in the current study
| Treatment | Dataset | Age, y | Volume, mL | Overall Survival, days |
|---|---|---|---|---|
| Chemoradiation | Discovery—UCLA (N = 398) | 56.1 ± 0.6 SEM | 10.2 ± 0.6 SEM | 878 ± 42 SEM |
| MGMT Methylation Status Available (N = 52; 16 = M, 36 = U) | Median = 5.6 | Median = 613 | ||
| Chemoradiation | Confirmation—Ivy Radiogenomics (N = 262) | 59.1 ± 0.8 SEM | 6.2 ± 0.5 SEM | 630 ± 30 SEM |
| MGMT Methylation Status Available (N = 0) | Median = 3.3 | Median = 490 | ||
| Chemoradiation | Validation—AVAglio PLC Arm (N = 394) | 55.5 ± 0.5 SEM | 17.2 ± 0.8 SEM | 546 ± 14 SEM |
| MGMT Methylation Status Available (N = 307; 108 = M, 199 = U) | Median = 10.9 | Median = 502 | ||
| Chemoradiation | AVAglio BV Arm (N = 404) | 55.6 ± 0.6 SEM | 15.7 ± 0.9 SEM | 570 ± 14 SEM |
| +Bevacizumab | MGMT Methylation Status Available (N = 303; 102 = M, 201 = U) | Median = 9.2 | Median = 506 | |
| Chemoradiation | Alliance N0874 (N = 53) | 59.2 ± 1.6 SEM | 10.9 ± 1.8 SEM | 676 ± 72 SEM |
| +Vorinostat | MGMT Methylation Status Available (N = 19; 11 = M, 8 = U) | Median = 6.6 | Median = 511 |
PLC = placebo; BV = bevacizumab; M = methylated; U = unmethylated; SEM = standard error about the mean